#GlobalCMTResearchConvention
The CMT Research Foundation unites the voices of patients, researchers, pharma companies, and regulatory agencies to develop treatments for CMT.
This event takes place over two days. Friday is a scientific meeting and is meant for researchers and scientists working in CMT. Saturday is primarily for patients and their families and caregivers, providing a chance to interact with the research community that is working so hard on their behalf and to better understand the latest in research progress.
For the Scientific Community
September 22nd
A day for researchers, industry and government agencies to:
SHARE the latest in CMT drug development research
CREATE new connections and collaborations
EXAMINE the most pressing issues facing CMT drug development
Click here to see the full agenda
Agenda
Click here to see the full day of event agenda
Chris Austin, MD, PhD
CEO-Partner of Flagship Pioneering,
Chief Executive Officer of Vesalius Therapeutics and
Founding Director of the National Center for Advancing Translational Sciences (NCATS)
Vera Fridman
University of Colorado
Rudolf Martini
University of Würzbug
Rachel Bailey
University of Texas Southwestern Medical Center
For the Patient Community
September 23rd
A day for the patient community to:
LEARN about the latest developments and clinical trials in CMT
INTERACT with distinguished scientific experts and clinicians
ACT to speed treatments for patients and families
Click here to see the full agenda
Agenda
Click here to see the full day of event agenda
Reza Seyedsadjadi, MD
Director, Charcot-Marie-Tooth (CMT) Center of Excellence, Massachusetts General Hospital
Assistant Professor of Neurology, Harvard Medical School
David Herrmann, MBBCh
Director, Charcot-Marie-Tooth (CMT) Center of Excellence, University of Rochester
Professor Department of Neurology, University of Rochester
Jim Lupski
Baylor College of Medicine
Katie Moss
Thomas Pedersen
NMD Pharma
Book your stay at the Royal Sonesta Boston with our special room rate here.
Thank You to Our Sponsors!
The Scientific Programming Committee
Marina Kennerson, PhD
Co-Chair
Professor of Neurogenetics and Neuroscience
ANZAC Research Institute and University of Sydney, Australia
Charles Abrams, MD, PhD
Co-Chair
Professor of Neurology and Rehabilitation
University of Illinois, Chicago (UIC)
Edritz Javelosa, PhD
Research Portfolio Director
Muscular Dystrophy Association
Paul August, PhD
Chief Scientific Officer
ReviR Therapeutics
Amanda Haidet-Phillips, PhD
Senior Director, Translational Medicine
Novartis Institutes for BioMedical Research
Dennis Klein, PhD
Research Scientist, Department of Neurology
University Hospital Wuerzburg, Germany
Glen Nuckolls, PhD
Program Director, Neurogenetics, Division of Neuroscience
U.S. National Institute of Neurological Disorders and Stroke (NINDS)
Tiina Urv, PhD
Program Director, Office of Rare Diseases Research
U.S. National Center for Advancing Translational Sciences (NCATS)
Alessandra Bolino, PhD
Group Leader, Human Inherited Neuropathies Unit
San Raffaele Scientific Institute, Milan, Italy
If you have any questions please contact Vanessa Sanchez at
[email protected] or +1 (404) 474-8805